No discrete molecular target – cell replacement and tissue-level support

This classification refers to therapeutic interventions that do not act upon a specific, discrete molecular target such as a protein, enzyme, or receptor (Santos et al., 2017, Nature Reviews Drug Discovery). Instead, the primary mechanism of action involves the replacement of damaged or missing cells and the provision of structural or functional support at the tissue level (NIH, 2023). This approach is characteristic of regenerative medicine and advanced therapy medicinal products (ATMPs), including stem cell transplants, tissue-engineered constructs, and certain cell-based therapies (FDA, 2022). \n\nThe therapeutic effect is achieved through the collective biological activity of the administered cells or the physical integration of the tissue graft into the host environment. Consequently, these treatments are evaluated based on their ability to restore complex physiological processes rather than their affinity for a single molecular entity (EMA, 2021). Safety considerations for these therapies often focus on long-term integration, potential for tumorigenicity, and immunological compatibility between the donor material and the recipient.

Other names

Cell replacement therapyTissue-level supportRegenerative medicineNon-molecular target therapyCellular therapy

Restoration of physiological function through the physical replacement of cells or tissues rather than pharmacological modulation of a specific molecular pathway (Santos et al., 2017, Nature Reviews Drug Discovery).